Key Takeaways From the 2024 DTRA Annual Meeting
December 12th 2024In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), shares her most important takeaways from the event including how industry is becoming more and more ready to adopt decentralized elements.
Themes Involving Clinical Trials at the 2024 DIA Global Annual Meeting
July 24th 2024In part 3 of this video interview, Carie Pierce, SVP, global head of growth & business development, DIA highlights the most relevant themes related to clinical trials that were present at DIA including DE&I and patient recruitment.
DIA Global Head of Growth Highlights Variety of Sessions at the 2024 Global Annual Meeting
July 23rd 2024Carie Pierce, SVP, global head of growth & business development, DIA touches on the various themes of the sessions which were held at the 2024 Global Annual Meeting including regulatory, technology, and harmonization.
DIA 2024: Ginny Beakes-Read of Johnson & Johnson Discusses Regulatory Challenges
June 21st 2024In an interview with ACT editor Andy Studna at DIA 2024, Beakes-Read, head, global regulatory policy and intelligence, Johnson & Johnson Innovative Medicine highlights the integration of technological advancements into drug development and benefits patients are seeing from FDA's Accelerated Approval Program.
DIA 2024: Allison Cuff Shimooka of TransCelerate Biopharma Discusses Innovation in Clinical Research
June 20th 2024In an interview with ACT editor Andy Studna at DIA 2024, Cuff Shimooka, chief operating officer of TransCelerate Biopharma touches on how collaboration will be key to innovation in clinical research moving forward.
DIA 2024: Rob DiCicco of TransCelerate Biopharma Discusses the State of AI in Clinical Research
June 19th 2024In an interview with ACT editor Andy Studna at DIA 2024, DiCicco, vice president, portfolio management, TransCelerate Biopharma highlights the use of artificial intelligence in clinical research from the perspectives of different stakeholders.
DIA 2024: Pat Hughes of CluePoints Highlights Renewed Agreement With FDA, Utilizing AI in RBQM
June 18th 2024In an interview with ACT editor Andy Studna at DIA 2024, Hughes, co-founder and chief commercial officer of CluePoints touches on collaboration with FDA and using artificial intelligence in clinical research.
DIA 2024: Gareth Dabbs of IQVIA Discusses Challenges With Clinical Technology
June 17th 2024In an interview with ACT editor Andy Studna at DIA 2024, Dabbs, vice president, global product strategy, IQVIA highlights challenges with tech overload and how stakeholders can choose which solution(s) are best for their studies.